It suggests that unlike patients with HIV, CD4+ T cell count < 200/μl cannot be used as a guide for preventive treatment of PJP in non-HIV immunocompromised patients, consistent with the findings of other scholars [7]. The gene discussed is CD4; the disease is pneumocystosis.